Literature DB >> 9624501

Mode of action of sulfanilyl fluoroquinolones.

F Alovero1, M Nieto, M R Mazzieri, R Then, R H Manzo.   

Abstract

The mode of action of sulfanilyl fluoroquinolones (NSFQs) was investigated with NSFQ-104, NSFQ-105, and some structurally related compounds. Evidence arising from interactions with p-aminobenzoic acid and trimethoprim suggested that a sulfonamidelike mechanism of action makes little or no contribution to the in vitro activity of NSFQs. NSFQ-105 showed an activity that inhibits gyrase-catalyzed DNA supercoiling that is similar to the activity of other fluoroquinolones. Also, NSFQ-105 uptake was decreased by the presence of Mg2+ and increased by a lower pH. These results indicate that NSFQs having only one ionizable group could exhibit more favorable kinetics of access to the bacterial cell than zwitterionic fluoroquinolones.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9624501      PMCID: PMC105629     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Quinolone antibacterial agents. Synthesis and structure-activity relationships of 8-substituted quinoline-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids.

Authors:  J P Sanchez; J M Domagala; S E Hagen; C L Heifetz; M P Hutt; J B Nichols; A K Trehan
Journal:  J Med Chem       Date:  1988-05       Impact factor: 7.446

Review 2.  Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples.

Authors:  H Nikaido; D G Thanassi
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

3.  Synergistic effect of quinolones and oxacillin on methicillin-resistant Staphylococcus species.

Authors:  P Rohner; C Herter; R Auckenthaler; J C Pechère; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

4.  Uptake of sparfloxacin and norfloxacin by clinical isolates of Staphylococcus aureus.

Authors:  S Yoshida; T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

5.  Fluorometric assay for fleroxacin uptake by bacterial cells.

Authors:  J S Chapman; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

6.  Effect of pyrimido[1,6-a]benzimidazoles, quinolones, and Ca2+ on the DNA gyrase-mediated cleavage reaction.

Authors:  H Gmünder; K Kuratli; W Keck
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

7.  Characterization of mutationally altered dihydropteroate synthase and its ability to form a sulfonamide-containing dihydrofolate analog.

Authors:  G Swedberg; S Castensson; O Sköld
Journal:  J Bacteriol       Date:  1979-01       Impact factor: 3.490

8.  In-vitro activity of new sulphanilil fluoroquinolones against Staphylococcus aureus.

Authors:  D A Allemandi; F L Alovero; R H Manzo
Journal:  J Antimicrob Chemother       Date:  1994-08       Impact factor: 5.790

9.  Transport of pefloxacin across the bacterial cytoplasmic membrane in quinolone-susceptible Staphylococcus aureus.

Authors:  Y X Furet; J Deshusses; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

10.  Quinolone accumulation in Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus.

Authors:  C McCaffrey; A Bertasso; J Pace; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

View more
  8 in total

1.  A Hybrid Drug Limits Resistance by Evading the Action of the Multiple Antibiotic Resistance Pathway.

Authors:  Kathy K Wang; Laura K Stone; Tami D Lieberman; Michal Shavit; Timor Baasov; Roy Kishony
Journal:  Mol Biol Evol       Date:  2015-11-03       Impact factor: 16.240

2.  Activity of newer fluoroquinolones in vitro against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1999       Impact factor: 9.546

3.  Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.

Authors:  F L Alovero; X S Pan; J E Morris; R H Manzo; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 4.  Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents.

Authors:  Julian Gregston Hurdle; Alexander John O'Neill; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus.

Authors:  Sandrine Lemaire; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

6.  Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.

Authors:  Xiao-Su Pan; Penelope J Hamlyn; Raquel Talens-Visconti; Fabiana L Alovero; Ruben H Manzo; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Pharmacological characterization of 7-(4-(Piperazin-1-yl)) ciprofloxacin derivatives: antibacterial activity, cellular accumulation, susceptibility to efflux transporters, and intracellular activity.

Authors:  Béatrice Marquez; Vincent Pourcelle; Coralie M Vallet; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Jacqueline Marchand-Bruynaert; Françoise Van Bambeke
Journal:  Pharm Res       Date:  2013-12-05       Impact factor: 4.200

8.  Synthesis, Antibacterial Evaluation and QSAR of α-Substituted-N₄-Acetamides of Ciprofloxacin and Norfloxacin.

Authors:  Amjad M Qandil; Lorca O Al-Zoubi; Amal G Al-Bakri; Haneen A Amawi; Qosay A Al-Balas; Abdulmalik M Alkatheri; Abdulkareem M Albekairy
Journal:  Antibiotics (Basel)       Date:  2014-06-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.